Dr. Jing Yang
The University of Texas MD Anderson Cancer Center
Department of Lymphoma and Myeloma
The main research focus of my laboratory is on studying the interaction of tumor cells with bone marrow microenvironment and the pathogenesis of bone destruction in multiple myeloma, and developing the potential therapeutic approaches for myeloma and its associated bone disease.
We investigated the ability of C-reactive protein
We demonstrated the contribution of p38 MAPK activation in myeloma cells to osteolytic bone lesions by activating osteoclastogenesis and inhibiting osteoblastogenesis in vivo. Our current studies are working on translating these results into providing better therapeutic targets.
In addition, one of our most compelling findings is developing monoclonal antibodies specific for human beta2 microglobulin and underlying that the antibodies remarkably induce myeloma cell apoptosis. Our results strong suggest the antibodies as a potential, novel therapeutic agent for the treatment of myeloma.